Werewolf Therapeutics, Inc.
NASDAQ:HOWL
2.72 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Werewolf Therapeutics, Inc. |
Symbool | HOWL |
Munteenheid | USD |
Prijs | 2.72 |
Beurswaarde | 118,869,984 |
Dividendpercentage | 0% |
52-weken bereik | 1.66 - 8.194 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Daniel J. Hicklin Ph.D. |
Website | https://werewolftx.com |
An error occurred while fetching data.
Over Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)